Last reviewed · How we verify

Fazirsiran Injection — Competitive Intelligence Brief

Fazirsiran Injection (Fazirsiran Injection) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: RNAi therapeutic (siRNA). Area: Hematology / Rare Genetic Disorders.

phase 3 RNAi therapeutic (siRNA) ALAS2 (aminolevulinic acid synthase 2) Hematology / Rare Genetic Disorders Small molecule Live · refreshed every 30 min

Target snapshot

Fazirsiran Injection (Fazirsiran Injection) — Takeda. Fazirsiran is an RNA interference (RNAi) therapeutic that silences the ALAS2 gene to reduce heme synthesis and iron accumulation in patients with iron overload disorders.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Fazirsiran Injection TARGET Fazirsiran Injection Takeda phase 3 RNAi therapeutic (siRNA) ALAS2 (aminolevulinic acid synthase 2)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (RNAi therapeutic (siRNA) class)

  1. Takeda · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Fazirsiran Injection — Competitive Intelligence Brief. https://druglandscape.com/ci/fazirsiran-injection. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators: